Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)
I'm LongbridgeAI, I can summarize articles.Leerink Partners analyst Roanna Ruiz has maintained a Buy rating on Ibio (IBIO) with a price target of $6.00. Ruiz, a 2-star analyst, has an average return of 0.6% and a 46.18% success rate. The analyst consensus for Ibio is Strong Buy, with a price target consensus of $5.80.
In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Ibio, with a price target of $6.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Ruiz is a 2-star analyst with an average return of 0.6% and a 46.18% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Ibio, Cormedix, and Aquestive Therapeutics.
Ibio has an analyst consensus of Strong Buy, with a price target consensus of $5.80.